Challenges in the Postmarket Surveillance of Clinical Prediction Models

临床预测模型上市后监测面临的挑战

阅读:2

Abstract

Predictive artificial intelligence (AI) models enhance clinical workflows with applications such as prognostication and decision support, yet suffer from postdeployment performance challenges due to dataset shifts. Regulatory guidelines emphasize the need for continuous monitoring, but actionable strategies are lacking. A significant issue is postdeployment assessment of predictive AI models due to confounding medical interventions where effective interventions modify outcomes, introducing bias into performance assessment. This can falsely suggest model decay, leading to unwarranted updates or decommissioning, harming clinical outcomes. Proposed solutions include withholding model outputs, monitoring outcomes as surrogates, or including clinician interventions in models, each with ethical or practical limitations. The lack of effective solutions for this problem can lead to an abundance of models that cannot be later evaluated, tuned, or withdrawn if they become ineffective, leading to patient harm. Advanced causal modeling to assess counterfactual outcomes may offer a reliable validation method. Until effective methods for postdeployment monitoring of predictive models are developed and validated, decisions on model updates should consider the causal pathways and be evidence based, ensuring the sustained utility of AI models in dynamic clinical environments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。